Mesoblast (Mesoblast) Accounts Payable : $10.76 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Accounts Payable?

Mesoblast's Accounts Payable for the quarter that ended in Dec. 2023 was $10.76 Mil.

Mesoblast's quarterly Accounts Payable declined from Jun. 2023 ($20.15 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($10.76 Mil).

Mesoblast's annual Accounts Payable increased from Jun. 2021 ($19.60 Mil) to Jun. 2022 ($23.08 Mil) but then declined from Jun. 2022 ($23.08 Mil) to Jun. 2023 ($20.15 Mil).

Mesoblast Accounts Payable Historical Data

The historical data trend for Mesoblast's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Accounts Payable Chart

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable

Get a 7-Day Free Trial

13.06

24.97

19.60

23.08

20.15

Mesoblast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable	Get a 7-Day Free Trial															22.99	20.97	20.15	-	10.76

Mesoblast Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Mesoblast Accounts Payable Related Terms

Thank you for viewing the detailed overview of Mesoblast's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

MESO:USA LWB:Germany MSB:Australia

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.